- Company
- US ITC bans Nabota from importing for 21 months
- by An, Kyung-Jin Dec 21, 2020 06:19am
- The US International Trade Commission (ITC) issued an order to ban imports from the US for 21 months on Jubo (Nabota), a botulinum toxin product developed by Daewoong. According to industry sources on the 17th, the US ITC issued a final ruling on the 16th (local time) in a lawsuit between Medy Tox and Daewoong infringement of trade secret
- Policy
- MOHW to reduce pricing in combination drug changing API
- by Kim, Jung-Ju Dec 21, 2020 06:19am
- The South Korean government is to reevaluate and reduce the reimbursed pricing on drugs that changed the main active pharmaceutical ingredient (API) due to the change of labeling. Immediately, calcium chloride combination injections are subjected to the new change with the updated list of reimbursed drug effective from Dec. 1. As it woul
- Policy
- Low dose in multiple Vizimpro reduces the insurance benefit
- by Lee, Hye-Kyung Dec 21, 2020 06:18am
- If Pfizer Korea's Vizimpro is prescribed at a low dose in multiple, the benefit will be reduced. The price difference between 1 tablet of Vizimpro 45mg (&8361;32,105/tab) and 3 tablets of Vizimpro 15mg (&8361;16,052/tab) is &8361;16,051, and the difference between 1 tabelt of Vizimpro 30mg and 2 tablets of Vizimpro 15mg is &8361;6,420
- Company
- Orally taken Rinvoq to be prescribed in general hospitals
- by Eo, Yun-Ho Dec 18, 2020 06:07am
- A third Janus kinase (JAK) inhibitor in South Korea, Rinvoq is swiftly seeking for prescription authorization in general hospitals nationwide immediately after it was listed for the healthcare reimbursement. An industry source reported AbbVie’s Rinvoq (upadacitinib) has been recently passed by the drug committees (DCs) at Seoul Asan Med
- Company
- When will K-COVID-19 vaccine be released?
- by Kim, Jin-Gu Dec 18, 2020 06:06am
- As Pfizer's COVID-19 vaccination has begun one after another in the UK and the US, interest in domestic companies that have jumped into COVID-19 vaccine development is also increasing. Currently, it is predicted that the commercialization of vaccines developed by domestic companies will be possible only in 2023 even if the commercializatio
- Opinion
- [Reporter's View] Pharmaceutical dept. needs independence
- by Lee, Hye-Kyung Dec 18, 2020 06:06am
- The 'Rules on the Standards for National Health Insurance Medical Care Benefits' revised and implemented by the MOHW on October 8 became the basis for negotiating all reimbursed drugs with the NHIS. At the time, the pharmaceutical industry could not realize the 'power' of the rule amendment, but the NHIS emphasized that all drugs that nee
- Company
- Drug export breaks record making near KRW 7 trillion
- by Kim, Jin-Gu Dec 18, 2020 06:05am
- The South Korean-made pharmaceutical export broke the record this year. The accumulated export volume up to November has already exceeded the total export volume in last year. Due to a steep surge in pharmaceutical export, the industry trade performance is expected to hit the highest point in the history. According to the Korea Customs Servi
- Policy
- Lee Nak-yon “Nationwide fast COVID-19 testing for all"
- by Lee, Jeong-Hwan Dec 18, 2020 06:05am
- The Democratic Party is to consult with the government and relevant experts to review the necessity of testing everyone in South Korea for COVID-19 via the fast antigen testing kits. At a National Assembly meeting for the political party leaders convened on Dec. 14, the ruling party leader Lee Nak-yon said, “It is time to discuss having
- Company
- Who distributes Pfizer-Moderna vaccine in South Korea?
- by Kim, Jin-Gu Dec 17, 2020 06:12am
- Just as Pfizer has, Moderna is getting close to receive the U.S. Food and Drug Administration’s (FDA) emergency use authorization for its COVID-19 vaccine. Currently, the South Korean government is in negotiation with two companies to supply their vaccines in the country. The attention is focused on how the vaccines would be manufacture
- Company
- Keytruda can be prescribed for TNBC patients in Korea
- by Eo, Yun-Ho Dec 17, 2020 06:11am
- It is expected to be able to prescribe Keytruda, an immune anticancer drug, to patients with triple-negative breast cancer (TNBC) in Korea. According to related industries, MSD Korea recently submitted an application for additional indications for the combination of chemotherapy in the first line therapy of metastatic TNBC of PD-1 inhibito
